HRP20230342T1 - Kationski lipid koji se može ionizirati za isporuku rna - Google Patents
Kationski lipid koji se može ionizirati za isporuku rna Download PDFInfo
- Publication number
- HRP20230342T1 HRP20230342T1 HRP20230342TT HRP20230342T HRP20230342T1 HR P20230342 T1 HRP20230342 T1 HR P20230342T1 HR P20230342T T HRP20230342T T HR P20230342TT HR P20230342 T HRP20230342 T HR P20230342T HR P20230342 T1 HRP20230342 T1 HR P20230342T1
- Authority
- HR
- Croatia
- Prior art keywords
- compound according
- consist
- branched alkyl
- cationic lipid
- carbon atoms
- Prior art date
Links
- -1 cationic lipid Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 10
- 125000000217 alkyl group Chemical group 0.000 claims 7
- 125000004432 carbon atom Chemical group C* 0.000 claims 4
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims 2
- 239000005977 Ethylene Substances 0.000 claims 2
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/60—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
- A61K48/0033—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being non-polymeric
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C333/00—Derivatives of thiocarbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C333/02—Monothiocarbamic acids; Derivatives thereof
- C07C333/04—Monothiocarbamic acids; Derivatives thereof having nitrogen atoms of thiocarbamic groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C333/00—Derivatives of thiocarbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C333/02—Monothiocarbamic acids; Derivatives thereof
- C07C333/10—Monothiocarbamic acids; Derivatives thereof having nitrogen atoms of thiocarbamic groups being part of any of the groups, X being a hetero atom, Y being any atom, e.g., N-acyl-thiocarbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0003—Androstane derivatives
- C07J1/0007—Androstane derivatives not substituted in position 17
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
- C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Dispersion Chemistry (AREA)
- Biophysics (AREA)
- Otolaryngology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14/546,105 US9593077B2 (en) | 2013-11-18 | 2014-11-18 | Ionizable cationic lipid for RNA delivery |
| US14/707,796 US9567296B2 (en) | 2013-11-18 | 2015-05-08 | Ionizable cationic lipid for RNA delivery |
| US14/707,876 US9365610B2 (en) | 2013-11-18 | 2015-05-08 | Asymmetric ionizable cationic lipid for RNA delivery |
| PCT/US2015/030218 WO2016081029A1 (en) | 2014-11-18 | 2015-05-11 | Ionizable cationic lipid for rna delivery |
| EP15724466.6A EP3221293B1 (en) | 2014-11-18 | 2015-05-11 | Ionizable cationic lipid for rna delivery |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20230342T1 true HRP20230342T1 (hr) | 2023-06-09 |
Family
ID=56014367
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20230342TT HRP20230342T1 (hr) | 2014-11-18 | 2015-05-11 | Kationski lipid koji se može ionizirati za isporuku rna |
Country Status (20)
| Country | Link |
|---|---|
| EP (1) | EP3221293B1 (enExample) |
| JP (1) | JP6637988B2 (enExample) |
| KR (1) | KR102380363B1 (enExample) |
| CN (1) | CN107207428A (enExample) |
| AU (1) | AU2015350561B2 (enExample) |
| CA (1) | CA2968060C (enExample) |
| DK (1) | DK3221293T3 (enExample) |
| ES (1) | ES2946110T3 (enExample) |
| FI (1) | FI3221293T3 (enExample) |
| HK (1) | HK1244479A1 (enExample) |
| HR (1) | HRP20230342T1 (enExample) |
| HU (1) | HUE062130T2 (enExample) |
| IL (1) | IL252291B (enExample) |
| LT (1) | LT3221293T (enExample) |
| NZ (1) | NZ732777A (enExample) |
| PL (1) | PL3221293T3 (enExample) |
| PT (1) | PT3221293T (enExample) |
| RS (1) | RS64078B1 (enExample) |
| SI (1) | SI3221293T1 (enExample) |
| WO (1) | WO2016081029A1 (enExample) |
Families Citing this family (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9593077B2 (en) | 2013-11-18 | 2017-03-14 | Arcturus Therapeutics, Inc. | Ionizable cationic lipid for RNA delivery |
| EP3957735A1 (en) | 2014-03-05 | 2022-02-23 | Editas Medicine, Inc. | Crispr/cas-related methods and compositions for treating usher syndrome and retinitis pigmentosa |
| US12460231B2 (en) | 2014-04-02 | 2025-11-04 | Editas Medicine, Inc. | Crispr/CAS-related methods and compositions for treating primary open angle glaucoma |
| CA3045134A1 (en) | 2016-12-14 | 2018-06-21 | Ligandal, Inc. | Compositions and methods for nucleic acid and/or protein payload delivery |
| US10526284B2 (en) | 2016-12-21 | 2020-01-07 | Arcturus Therapeutics, Inc. | Ionizable cationic lipid for RNA delivery |
| US10383952B2 (en) * | 2016-12-21 | 2019-08-20 | Arcturus Therapeutics, Inc. | Ionizable cationic lipid for RNA delivery |
| WO2018119163A1 (en) * | 2016-12-21 | 2018-06-28 | Payne Joseph E | Ionizable cationic lipid for rna delivery |
| EP3600396A4 (en) | 2017-03-30 | 2021-01-13 | The Government of the United States of America as represented by the Secretary of the Army | NUCLEIC ACID VACCINE COMPOSITION WITH A LIPID FORMULATION AND METHOD FOR INCREASING THE POTENTIAL OF NUCLEIC ACID VACCINE |
| WO2018222890A1 (en) * | 2017-05-31 | 2018-12-06 | Arcturus Therapeutics, Inc. | Synthesis and structure of high potency rna therapeutics |
| EP3773476A1 (en) * | 2018-03-30 | 2021-02-17 | Arcturus Therapeutics, Inc. | Lipid particles for nucleic acid delivery |
| EP3784284B1 (en) | 2018-04-25 | 2023-08-02 | Ethris GmbH | Lipid-based formulations for the delivery of rna |
| KR20190127277A (ko) * | 2018-05-04 | 2019-11-13 | 주식회사 삼양바이오팜 | mRNA 전달용 고분자 나노입자 조성물 및 그 제조방법 |
| PL3805198T3 (pl) | 2018-06-08 | 2024-02-12 | Fujifilm Corporation | Związek, jego sól i cząstki lipidowe |
| CA3122080A1 (en) | 2018-12-06 | 2020-06-11 | Arcturus Therapeutics, Inc. | Compositions and methods for treating ornithine transcarbamylase deficiency |
| BR112021018526A2 (pt) * | 2019-03-19 | 2021-11-23 | Arcturus Therapeutics Inc | Método de fabricação de nanopartículas de rna encapsuladas em lipídio |
| EP3981435B1 (en) | 2019-06-07 | 2023-08-16 | FUJIFILM Corporation | Lipid composition |
| WO2021067598A1 (en) | 2019-10-04 | 2021-04-08 | Ultragenyx Pharmaceutical Inc. | Methods for improved therapeutic use of recombinant aav |
| EP4328309B1 (en) | 2019-11-15 | 2025-07-02 | FUJIFILM Corporation | Lipid composition |
| WO2021178510A1 (en) | 2020-03-03 | 2021-09-10 | Arcturus Therapeutics, Inc. | Compositions and methods for the treatment of ornithine transcarbamylase deficiency |
| IL296660A (en) | 2020-03-24 | 2022-11-01 | Generation Bio Co | Non-viral dna vectors and uses thereof for expressing factor ix therapeutics |
| CA3172591A1 (en) | 2020-03-24 | 2021-09-30 | Douglas Anthony KERR | Non-viral dna vectors and uses thereof for expressing gaucher therapeutics |
| JP2023530487A (ja) * | 2020-06-18 | 2023-07-18 | アークトゥラス・セラピューティクス・インコーポレイテッド | ポリグルタミン病の治療のためのｕｎａオリゴマー |
| EP4189098A1 (en) | 2020-07-27 | 2023-06-07 | Anjarium Biosciences AG | Compositions of dna molecules, methods of making therefor, and methods of use thereof |
| JP7774615B2 (ja) | 2020-09-13 | 2025-11-21 | アークトゥラス・セラピューティクス・インコーポレイテッド | 大型ｒｎａの脂質ナノ粒子封入 |
| MX2023009345A (es) | 2021-02-10 | 2023-10-24 | Oncorus Inc | Compuestos, composiciones y metodos de uso de estos. |
| AU2022260111A1 (en) | 2021-04-20 | 2023-11-30 | Anjarium Biosciences Ag | Compositions of dna molecules encoding amylo-alpha-1, 6-glucosidase, 4-alpha-glucanotransferase, methods of making thereof, and methods of use thereof |
| AU2022264509A1 (en) | 2021-04-27 | 2023-12-14 | Generation Bio Co. | Non-viral dna vectors expressing therapeutic antibodies and uses thereof |
| EP4329884A1 (en) | 2021-04-27 | 2024-03-06 | Generation Bio Co. | Non-viral dna vectors expressing anti-coronavirus antibodies and uses thereof |
| EP4395748A1 (en) | 2021-09-03 | 2024-07-10 | CureVac SE | Novel lipid nanoparticles for delivery of nucleic acids |
| US20250027108A1 (en) | 2021-10-29 | 2025-01-23 | CureVac SE | Improved circular rna for expressing therapeutic proteins |
| TW202334080A (zh) | 2021-11-08 | 2023-09-01 | 美商歐納醫療公司 | 用於遞送環狀聚核苷酸之脂質奈米粒子組合物 |
| WO2023135273A2 (en) | 2022-01-14 | 2023-07-20 | Anjarium Biosciences Ag | Compositions of dna molecules encoding factor viii, methods of making thereof, and methods of use thereof |
| EP4469091A1 (en) | 2022-01-28 | 2024-12-04 | CureVac SE | Nucleic acid encoded transcription factor inhibitors |
| CN114213295B (zh) * | 2022-02-22 | 2022-05-20 | 中国科学院基础医学与肿瘤研究所(筹) | 一种阳离子化合物、制备方法及其复合物和用途 |
| CN119072330A (zh) | 2022-03-14 | 2024-12-03 | 世代生物公司 | 异源初免加强疫苗组合物和使用方法 |
| US20250345407A1 (en) | 2022-05-25 | 2025-11-13 | CureVac SE | Nucleic acid based vaccine encoding an escherichia coli fimh antigenic polypeptide |
| AU2023283348A1 (en) | 2022-06-07 | 2025-01-09 | Generation Bio Co. | Lipid nanoparticle compositions and uses thereof |
| WO2024040222A1 (en) | 2022-08-19 | 2024-02-22 | Generation Bio Co. | Cleavable closed-ended dna (cedna) and methods of use thereof |
| IL319704A (en) | 2022-09-23 | 2025-05-01 | Nchroma Bio Inc | Compositions and methods for epigenetic regulation of HBV gene expression |
| US12186389B2 (en) | 2022-10-28 | 2025-01-07 | Glaxosmithkline Biologicals Sa | Nucleic acid base vaccine against emerging SARS-CoV-2 variants |
| WO2024102762A1 (en) | 2022-11-08 | 2024-05-16 | Orna Therapeutics, Inc. | Lipids and lipid nanoparticle compositions for delivering polynucleotides |
| TW202425959A (zh) | 2022-11-08 | 2024-07-01 | 美商歐納醫療公司 | 遞送多核苷酸的脂質及奈米顆粒組合物 |
| JP2025537178A (ja) | 2022-11-08 | 2025-11-14 | オーナ セラピューティクス， インコーポレイテッド | 環状ｒｎａ組成物 |
| EP4626444A2 (en) | 2022-12-01 | 2025-10-08 | Generation Bio Co. | Lipid nanoparticles comprising nucleic acids, ionizable lipids, sterols, lipid anchored polymers and helper lipids, their uses |
| IL320873A (en) | 2022-12-01 | 2025-07-01 | Generation Bio Co | Novel polyglycerol-conjugated lipids and lipid nanoparticle compositions containing them |
| EP4626402A1 (en) | 2022-12-01 | 2025-10-08 | Generation Bio Co. | Lipid nanoparticles comprising nucleic acids and lipid-anchored polymers |
| CN120615013A (zh) | 2022-12-01 | 2025-09-09 | 世代生物公司 | 用于细胞靶向的隐形脂质纳米颗粒组合物 |
| AU2024233180A1 (en) | 2023-03-08 | 2025-09-25 | CureVac SE | Novel lipid nanoparticle formulations for delivery of nucleic acids |
| WO2024205657A2 (en) | 2023-03-29 | 2024-10-03 | Orna Therapeutics, Inc. | Lipids and lipid nanoparticle compositions for delivering polynucleotides |
| AU2024269222A1 (en) | 2023-05-05 | 2025-10-09 | Orna Therapeutics, Inc. | Circular rna compositions and methods |
| WO2024230934A1 (en) | 2023-05-11 | 2024-11-14 | CureVac SE | Therapeutic nucleic acid for the treatment of ophthalmic diseases |
| EP4713453A1 (en) | 2023-05-15 | 2026-03-25 | nChroma Bio, Inc. | Compositions and methods for epigenetic regulation of hbv gene expression |
| CN116270543B (zh) * | 2023-05-19 | 2023-09-26 | 清华大学 | 脂质纳米颗粒在制备通过雾吸或鼻滴给药递送核酸的药物中的用途 |
| CN121666232A (zh) | 2023-05-31 | 2026-03-13 | 开普斯坦治疗公司 | 脂质纳米颗粒制剂和组合物 |
| WO2025049690A1 (en) | 2023-08-29 | 2025-03-06 | Orna Therapeutics, Inc. | Circular polyethylene glycol lipids |
| WO2025052180A2 (en) | 2023-09-07 | 2025-03-13 | Axelyf ehf. | Lipids and lipid nanoparticles |
| WO2025080939A1 (en) | 2023-10-13 | 2025-04-17 | Ultragenyx Pharmaceutical, Inc. | Compositions and methods for treating conditions associated with cartilage oligomeric matrix protein (comp) mutations |
| WO2025101501A1 (en) | 2023-11-07 | 2025-05-15 | Orna Therapeutics, Inc. | Circular rna compositions |
| WO2025128853A2 (en) | 2023-12-13 | 2025-06-19 | Ultragenyx Pharmaceutical Inc. | Compositions and methods for treating conditions associated with ube3a overexpression |
| US20250332281A2 (en) | 2023-12-15 | 2025-10-30 | Capstan Therapeutics, Inc. | Humanized anti-cd8 antibodies and uses thereof |
| WO2025166325A1 (en) | 2024-02-02 | 2025-08-07 | Editas Medicine, Inc. | MODIFIED GUIDE RNAs |
| US20250381150A1 (en) | 2024-03-08 | 2025-12-18 | Genzyme Corporation | Lipid nanoparticles |
| WO2025213138A1 (en) | 2024-04-05 | 2025-10-09 | Editas Medicine, Inc. | Crispr/rna-guided nuclease related methods and compositions for treating primary open angle glaucoma |
| WO2026003582A2 (en) | 2024-06-27 | 2026-01-02 | Axelyf ehf. | Lipids and lipid nanoparticles |
| WO2026030375A2 (en) | 2024-07-30 | 2026-02-05 | Genzyme Corporation | Lipid nanoparticles and methods of manufacture and use thereof |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE21633T1 (de) | 1981-06-04 | 1986-09-15 | Pharmasol Corp | Druckbehaelter mit abgabepumpe. |
| US4778810A (en) | 1987-01-08 | 1988-10-18 | Nastech Pharmaceutical Co., Inc. | Nasal delivery of caffeine |
| JP3257675B2 (ja) | 1990-10-12 | 2002-02-18 | マックス−プランク−ゲゼルシャフト ツール フェルデルング デル ビッセンシャフテン エー．ファウ． | 修飾リボザイム |
| US5652094A (en) | 1992-01-31 | 1997-07-29 | University Of Montreal | Nucleozymes |
| US5849902A (en) | 1996-09-26 | 1998-12-15 | Oligos Etc. Inc. | Three component chimeric antisense oligonucleotides |
| US9408914B2 (en) * | 2010-04-28 | 2016-08-09 | Kyowa Hakko Kirin Co., Ltd. | Cationic lipid |
| AU2012267467B8 (en) * | 2011-06-08 | 2017-06-15 | Nitto Denko Corporation | Compounds for targeting drug delivery and enhancing siRNA activity |
| US20140308304A1 (en) * | 2011-12-07 | 2014-10-16 | Alnylam Pharmaceuticals, Inc. | Lipids for the delivery of active agents |
| CA2876148C (en) * | 2012-06-08 | 2021-01-12 | Nitto Denko Corporation | Lipids for therapeutic agent delivery formulations |
| US9593077B2 (en) * | 2013-11-18 | 2017-03-14 | Arcturus Therapeutics, Inc. | Ionizable cationic lipid for RNA delivery |
-
2015
- 2015-05-11 NZ NZ732777A patent/NZ732777A/en unknown
- 2015-05-11 DK DK15724466.6T patent/DK3221293T3/da active
- 2015-05-11 RS RS20230231A patent/RS64078B1/sr unknown
- 2015-05-11 ES ES15724466T patent/ES2946110T3/es active Active
- 2015-05-11 HU HUE15724466A patent/HUE062130T2/hu unknown
- 2015-05-11 HK HK18103903.0A patent/HK1244479A1/zh unknown
- 2015-05-11 SI SI201531935T patent/SI3221293T1/sl unknown
- 2015-05-11 PL PL15724466.6T patent/PL3221293T3/pl unknown
- 2015-05-11 PT PT157244666T patent/PT3221293T/pt unknown
- 2015-05-11 AU AU2015350561A patent/AU2015350561B2/en active Active
- 2015-05-11 CA CA2968060A patent/CA2968060C/en active Active
- 2015-05-11 EP EP15724466.6A patent/EP3221293B1/en active Active
- 2015-05-11 CN CN201580073670.9A patent/CN107207428A/zh active Pending
- 2015-05-11 FI FIEP15724466.6T patent/FI3221293T3/fi active
- 2015-05-11 LT LTEPPCT/US2015/030218T patent/LT3221293T/lt unknown
- 2015-05-11 KR KR1020177016742A patent/KR102380363B1/ko active Active
- 2015-05-11 JP JP2017545520A patent/JP6637988B2/ja active Active
- 2015-05-11 WO PCT/US2015/030218 patent/WO2016081029A1/en not_active Ceased
- 2015-05-11 HR HRP20230342TT patent/HRP20230342T1/hr unknown
-
2017
- 2017-05-15 IL IL252291A patent/IL252291B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2017535610A (ja) | 2017-11-30 |
| KR102380363B1 (ko) | 2022-03-29 |
| PT3221293T (pt) | 2023-03-16 |
| IL252291B (en) | 2021-08-31 |
| DK3221293T3 (da) | 2023-04-03 |
| EP3221293B1 (en) | 2023-03-01 |
| WO2016081029A1 (en) | 2016-05-26 |
| HUE062130T2 (hu) | 2023-09-28 |
| NZ732777A (en) | 2023-06-30 |
| CA2968060C (en) | 2023-06-20 |
| IL252291A0 (en) | 2017-07-31 |
| CA2968060A1 (en) | 2016-05-26 |
| AU2015350561B2 (en) | 2020-01-30 |
| SI3221293T1 (sl) | 2023-05-31 |
| HK1244479A1 (zh) | 2018-08-10 |
| EP3221293A1 (en) | 2017-09-27 |
| JP6637988B2 (ja) | 2020-01-29 |
| RS64078B1 (sr) | 2023-04-28 |
| KR20170095241A (ko) | 2017-08-22 |
| AU2015350561A1 (en) | 2017-07-06 |
| CN107207428A (zh) | 2017-09-26 |
| LT3221293T (lt) | 2023-03-27 |
| FI3221293T3 (fi) | 2023-04-05 |
| ES2946110T3 (es) | 2023-07-12 |
| PL3221293T3 (pl) | 2023-07-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20230342T1 (hr) | Kationski lipid koji se može ionizirati za isporuku rna | |
| HRP20221536T1 (hr) | Novi lipidi i formulacije lipidnih nanočestica za isporuku nukleinskih kiselina | |
| HRP20231742T1 (hr) | Kationski lipid koji se može ionizirati za isporuku rna | |
| HRP20241239T1 (hr) | Novi heterociklički derivati korisni kao shp2 inhibitori | |
| HRP20250181T1 (hr) | Spojevi i postupci za ciljanu razgradnju receptora androgena | |
| ME03404B (me) | Derivati policikličnih amida kao cdk9 inhibitori | |
| MX377255B (es) | Lipidos y composiciones de lipidos para el suministro de agentes activos. | |
| HRP20210529T1 (hr) | Inhibitori za mk2 i njihove uporabe | |
| MX2016007522A (es) | Estimuladores de guanilato ciclasa soluble (sgc). | |
| MX354175B (es) | Derivados de imidazotiadiazol e imidazopirazina como inhibidores del receptor activado de proteasa 4 (par4) para el tratamiento de agregacion plaquetaria. | |
| MX2016005855A (es) | Compuestos de conjugados antisentido de apolipoproteina b (apob). | |
| NZ720174A (en) | Ionizable cationic lipid for rna delivery | |
| PH12016500806A1 (en) | Urea derivative or pharmacologically acceptable salt thereof | |
| ES2626555T3 (es) | Pyridone amides como moduladores de canales de sodio | |
| EP4643945A3 (en) | Neuroactive steroids and methods of use thereof | |
| MX373716B (es) | Compuesto de pirazol-amida y sus usos farmaceuticos. | |
| MX2013010046A (es) | Administracion parenteral de tapentadol. | |
| MX380546B (es) | Derivados de pirazolopirimidona o pirrolotriazona, metodo y preparacion de los mismos y aplicaciones farmaceuticas de los mismos. | |
| TN2016000061A1 (en) | Amide derivatives as lysophosphatidic acid receptor antagonists | |
| FR3010147B1 (fr) | Suspension isostatique d'un turboreacteur par double support arriere | |
| PL3509573T3 (pl) | Kompozycje farmaceutyczne do dostarczania peptydu | |
| MX373162B (es) | Piridopirimidinonas y utilización de las mismas como moduladores de receptores de n-metil-d-aspartato (nmda). | |
| PH12015502632A1 (en) | Cxcr7 receptor modulators | |
| EP2994476A4 (en) | STRUCTURE-BASED PEPTIDINHIBITORS OF THE P53 AGGREGATION AS A NEW APPROACH TO CANCER THERAPEUTICS | |
| EP3318259A4 (en) | STABLE PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION |